Literature DB >> 10570115

Cognition, schizophrenia, and the atypical antipsychotic drugs.

H Y Meltzer1, S Park, R Kessler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10570115      PMCID： PMC33933          DOI： 10.1073/pnas.96.24.13591

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  39 in total

1.  Dopamine2 receptor occupancy and the action of clozapine: does it make a difference to add a neuroleptic?

Authors:  H Y Meltzer
Journal:  Biol Psychiatry       Date:  1999-07-01       Impact factor: 13.382

2.  Is it possible to be schizophrenic yet neuropsychologically normal?

Authors:  B W Palmer; R K Heaton; J S Paulsen; J Kuck; D Braff; M J Harris; S Zisook; D V Jeste
Journal:  Neuropsychology       Date:  1997-07       Impact factor: 3.295

3.  Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine.

Authors:  J D Jentsch; D E Redmond; J D Elsworth; J R Taylor; K D Youngren; R H Roth
Journal:  Science       Date:  1997-08-15       Impact factor: 47.728

4.  Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.

Authors:  A Schotte; P F Janssen; W Gommeren; W H Luyten; P Van Gompel; A S Lesage; K De Loore; J E Leysen
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

5.  Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values.

Authors:  H Y Meltzer; S Matsubara; J C Lee
Journal:  J Pharmacol Exp Ther       Date:  1989-10       Impact factor: 4.030

Review 6.  Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia.

Authors:  H E Spohn; M E Strauss
Journal:  J Abnorm Psychol       Date:  1989-11

Review 7.  Cognitive improvement in schizophrenia with novel antipsychotic medications.

Authors:  S E Purdon
Journal:  Schizophr Res       Date:  1999-03-01       Impact factor: 4.939

8.  Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia.

Authors:  G D Honey; E T Bullmore; W Soni; M Varatheesan; S C Williams; T Sharma
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

9.  Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine.

Authors:  C Hagger; P Buckley; J T Kenny; L Friedman; D Ubogy; H Y Meltzer
Journal:  Biol Psychiatry       Date:  1993-11-15       Impact factor: 13.382

10.  Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials.

Authors:  S Leucht; G Pitschel-Walz; D Abraham; W Kissling
Journal:  Schizophr Res       Date:  1999-01-04       Impact factor: 4.939
View more
  21 in total

1.  Novel allosteric agonists of M1 muscarinic acetylcholine receptors induce brain region-specific responses that correspond with behavioral effects in animal models.

Authors:  Gregory J Digby; Meredith J Noetzel; Michael Bubser; Thomas J Utley; Adam G Walker; Nellie E Byun; Evan P Lebois; Zixiu Xiang; Douglas J Sheffler; Hyekyung P Cho; Albert A Davis; Natali E Nemirovsky; Sarah E Mennenga; Bryan W Camp; Heather A Bimonte-Nelson; Jacob Bode; Kimberly Italiano; Ryan Morrison; J Scott Daniels; Colleen M Niswender; M Foster Olive; Craig W Lindsley; Carrie K Jones; P Jeffrey Conn
Journal:  J Neurosci       Date:  2012-06-20       Impact factor: 6.167

2.  Intra-prefrontal 8-OH-DPAT and M100907 improve visuospatial attention and decrease impulsivity on the five-choice serial reaction time task in rats.

Authors:  Catharine A Winstanley; Yogita Chudasama; Jeffrey W Dalley; David E H Theobald; Jeffrey C Glennon; Trevor W Robbins
Journal:  Psychopharmacology (Berl)       Date:  2003-04-02       Impact factor: 4.530

3.  Hippocampal place cell and inhibitory neuron activity in Disrupted-in-schizophrenia-1 mutant mice: implications for working memory deficits.

Authors:  Lia Mesbah-Oskui; John Georgiou; John C Roder
Journal:  NPJ Schizophr       Date:  2015-04-01

4.  F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. I. In vitro receptor affinity and efficacy profile.

Authors:  A Newman-Tancredi; M-B Assié; J-C Martel; C Cosi; L Bruins Slot; C Palmier; I Rauly-Lestienne; F Colpaert; B Vacher; D Cussac
Journal:  Br J Pharmacol       Date:  2007-03-20       Impact factor: 8.739

Review 5.  Measuring changes in functional status among patients with schizophrenia: the link with cognitive impairment.

Authors:  Louis S Matza; Robert Buchanan; Scot Purdon; Jessica Brewster-Jordan; Yang Zhao; Dennis A Revicki
Journal:  Schizophr Bull       Date:  2006-07-07       Impact factor: 9.306

Review 6.  Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction.

Authors:  Patricia S Goldman-Rakic; Stacy A Castner; Torgny H Svensson; Larry J Siever; Graham V Williams
Journal:  Psychopharmacology (Berl)       Date:  2004-04-30       Impact factor: 4.530

7.  Synergistic dopamine increase in the rat prefrontal cortex with the combination of quetiapine and fluvoxamine.

Authors:  Damiaan Denys; André A Klompmakers; Herman G M Westenberg
Journal:  Psychopharmacology (Berl)       Date:  2004-05-11       Impact factor: 4.530

Review 8.  Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders.

Authors:  Bryan L Roth; S Mohammad Hanizavareh; Andrew E Blum
Journal:  Psychopharmacology (Berl)       Date:  2003-12-02       Impact factor: 4.530

Review 9.  Animal models of working memory: insights for targeting cognitive dysfunction in schizophrenia.

Authors:  Stacy A Castner; Patricia S Goldman-Rakic; Graham V Williams
Journal:  Psychopharmacology (Berl)       Date:  2004-01-20       Impact factor: 4.530

Review 10.  Should cognitive deficit be a diagnostic criterion for schizophrenia?

Authors:  Ralph Lewis
Journal:  J Psychiatry Neurosci       Date:  2004-03       Impact factor: 6.186
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.